1.25 million Americans have type 1 diabetes (T1D), where the immune system destroys insulin- producing beta cells. Transplantation of islets into patients with type 1 diabetes as a curative measure has yet to overcome the barrier of immune-mediated destruction of the transplanted cells. Islet transplantation requires a drug regiment to suppress the immune response from allorejection, resulting in chronic immunosuppression with its own severe complications. Thus, targeted immunotherapy to prevent immune- mediated attack on transplanted islets without systemic immunosuppression would be ideal. Immunotherapies to date have targeted the adaptive immune response (T and B cells), ignoring the innate immune system (neutrophils, monocytes and macrophages). Siglecs are a family of sialic acid binding proteins, each with a preference for a particular type of sialic acid moiety on the cell surface. Siglec-E is an inhibitory receptor expressed on neutrophils, monocytes and macrophages that functions to block inflammation. Therefore, engagement of Siglec-E by innate immune cells could promote immune tolerance rather than inflammation and immune activation, which may be a novel approach to treat T1D. We have demonstrated that the sialyltransferase ST8Sia6 generates ?2,8 linked disialic acids on O-linked glycoproteins which are recognized specifically by Siglec-E. ST8Sia6 knockout mice have decreased recombinant Siglec-E binding to T cells. We hypothesized that expression of ST8Sia6 could inhibit the immune response by generating ligands for Siglec-E on the cell surface. To test this, we generated a novel line of mice in our laboratory where ST8Sia6 is constitutively overexpressed only in pancreatic ? cells (?RIP- cre LNL-tTA ST8Sia6?). RIP-cre LNL-tTA ST8Sia6 mice are healthy, have resting blood glucose levels indistinguishable from littermate controls, and respond normally to a glucose tolerance test. Therefore, constitutive expression of ST8Sia6 in pancreatic ? cells does not interfere with ? cell function or survival. To test whether constitutive ST8Sia6 expression could be protective, we utilized the multiple low dose streptozocin (STZ) model to induce diabetes, which has a strong pro-inflammatory component. We demonstrated that targeted expression of ST8Sia6 in pancreatic ? cells provided protection from diabetes induced using MLD-STZ. The median onset to diabetes was 28 days for ST8Sia6-expressing mice as compared to 18.5 days for littermate controls. In addition, the hyperglycemia was less severe in ST8Sia6- expressing mice. Thus, ST8Sia6 expression provides protection in the MLD-STZ model of diabetes. The focus of this proposal is to target ST8Sia6 expression in ? cells in autoimmune models to show protection from immune-mediated attack.

Public Health Relevance

Approximately 1.25 million Americans have Type 1 Diabetes, where the immune system targets insulin- producing ? cells within the islets of Langerhans for destruction, and there is no cure as we do not know how to stop this immune-mediated attack. We propose that the generation of ligands for the inhibitory Siglec, Siglec-E, may prevent immune mediated attack by blocking inflammation generated by the innate arm of the immune system. We have generated a novel mouse model in which the sialic acid transferase ST8Sia6, which leads to generation of ligands that bind to Siglec-E, is ectopically expressed in pancreatic ? cells.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Bourcier, Katarzyna
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code